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Abstract 
 
The transcription factor Nrf2 regulates the basal and inducible expression of numerous cell defence genes, 
and thus protects mammalian cells against the deleterious effects of chemical and oxidative stress. Here, we 
provide a concise overview of the role of Nrf2 in protection against drug and chemical toxicity, with a focus 
on the numerous in vivostudies that have shown heightened sensitivity of Nrf2 null (knockout) transgenic 
mice to such insults. In light of the emerging role for Nrf2 in driving drug resistance in cancer, we also consider 
the potential benefits and risks of modulating Nrf2 activity to overcome chemoresistance in patients. Finally, 
we highlight recent efforts to monitor perturbation of the Nrf2 pathway in vitro as part of integrated risk 
assessment strategies designed to identify compounds that are hazardous to human health. 
 
1. Introduction 
 
Drug and chemical toxicity represent a significant human health hazard, with the former limiting the 
development and use of otherwise effective medicines [1]. Oxidative stress underpins the toxic effects of 
many chemical entities. However, mammalian cells are equipped with an antioxidant stress response 
pathway, regulated by the transcription factor nuclear factor erythroid 2 related factor 2 (Nrf2), to counteract 
the deleterious effects of oxidative stress. Here, we provide a brief overview of the Nrf2 pathway (other 
articles in this themed issue provide more detailed descriptions of molecular and regulatory features) and 
highlight its role in protection against drug and chemical toxicity. 
 
2. The Nrf2 pathway 
 
Nrf2 is a member of the cap ‘n’ collar (CNC) family of basic leucine zipper (bZIP) transcription factors that is 
evolutionarily conserved and expressed in essentially all tissues. Under normal conditions, Nrf2 is 
sequestered in the cytoplasm and targeted for ubiquitination and proteasomal degradation by its repressor 
Kelch-like ECH-associated protein 1 (Keap1). Under conditions of chemical or oxidative stress, reactive 
cysteine residues in Keap1 undergo redox modification, inhibiting Keap1-mediated degradation of Nrf2 and 
stabilising the transcription factor (Figure 1). The resulting accumulation of Nrf2 in the nucleus facilitates 
interaction with small Maf proteins and increases the transcription of cytoprotective genes that poses one 
or more antioxidant responsive elements (AREs) in their promoter regions [2]. More than 100 Nrf2-regulated 
genes have been identified to date, with many contributing to homeostatic processes including xenobiotic 
metabolism, glutathione synthesis/recycling, antioxidation and the provision of cellular fuels (Table 1). A role 
for Nrf2 in the regulation of these processes has largely been established through omics analyses of organs 
from transgenic Nrf2−/− mice, as we recently reported for the kidney [3]. By regulating the basal and inducible 
expression of this diverse set of genes, Nrf2 influences cell and organism sensitivity to a range of chemical 
and oxidative insults (Figure 1). 
 
2 
 
 
 
Figure 1 – The Nrf2 pathway and its influence on drug and chemical toxicity. (A) In response to 
chemical/oxidative stress, Nrf2 evades Keap1-mediated repression and accumulates in the nucleus, where it 
dimerises with small Maf proteins and transactivates cytoprotective target genes that serve to detoxify the 
original insult and limit its deleterious effects. (B) Examples of drug and chemical toxicities against which Nrf2 
protects, based on evidence from in vivo studies using Nrf2-/- mice (see Table 2 for other examples).  
 
 
Class Example Gene Example Gene Function 
Phase I drug 
metabolism 
NAD(P)H dehydrogenase 
quinone 1 (Nqo1) 
Reduces reactive quinones to hydroquinones. 
Phase II drug 
metabolism 
UDP-glucuronyltransferases 1 
family polypeptide A (Ugt1a1) 
Catalyses conjugation of drugs and small molecules with 
glucuronic acid, increasing hydrophilicity. 
Phase III drug 
metabolism 
ATP-binding cassette sub-family 
C, member 1  (Abcc1) 
Effluxes drugs and other small molecules from cells. 
Glutathione 
metabolism 
Glutamate cysteine ligase, 
catalytic subunit (Gclc) 
Rate limiting enzyme in synthesis of glutathione, the major 
antioxidant in cells. 
Antioxidant 
processes 
Sulfiredoxin 1 (Srxn1) Reduces oxidative modifications of cysteine residues in 
peroxiredoxins. 
Heme 
metabolism 
Heme oxygenase 1 (Hmox1) Converts toxic free heme to biliverdin (subsequently 
converted to antioxidants bilirubin and carbon monoxide).  
NADPH 
metabolism 
6-Phosphogluconate 
dehydrogenase (Pgd) 
Catalyses one step of pentose phosphate pathway. 
 
Table 1 – Major classes and examples of cytoprotective genes regulated by Nrf2. For details of these and 
other relevant genes, see [2]. 
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3. Nrf2 protects against drug and chemical toxicity – Positive aspects 
 
The first in vivo demonstration of the protective effect of Nrf2 was in 1999, when Chan and Kan showed that 
Nrf2−/− mice developed acute respiratory distress syndrome following exposure to doses of butylated 
hydroxytoluene that were tolerated by wild type mice [4]. This was soon followed by reports that Nrf2−/− mice 
were highly sensitive to the model liver toxin acetaminophen 5 and 6, shown subsequently to be a result of 
an increase in its conversion to the reactive metabolite N-acetyl-p-benzoquinoneimine and a decrease in 
hepatic detoxification capacity [7]. To date, a large number of substances (Table 2) have been shown to 
provoke greater toxicity in major organs of Nrf2−/− mice, which lack Nrf2 in all tissues. Whilst many of these 
substances (e.g. carbon tetrachloride, ovalbumin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) are 
primarily experimental tools used to study organ injury, several investigations have focused on the role of 
Nrf2 in protection against environmental agents (e.g. diquat dibromide, cigarette smoke, benzo[a]pyrene) or 
therapeutic drugs (e.g. bleomycin, methamphetamine, cisplatin) with adverse effects that are relevant to 
man. The large body of evidence from studies using Nrf2−/− mice has been further supported by investigations 
involving the genetic or pharmacological upregulation of Nrf2 activity. For example, both hepatocyte-specific 
loss of the Keap1 gene [8] and pre-treatment with the triterpenoid Nrf2 inducer 2-cyano-3,12-dioxooleana-
1,9-dien-28-oic imidazolide (CDDO-Im; [9]) affords protection against acetaminophen liver injury. Therefore, 
whilst some organs (e.g. liver and lung) have been studied more extensively than others, it is clear that Nrf2 
exerts a general protective effect against drug and chemical toxicity in mice (Figure 1). Based on these 
observations and work in human cell systems, there is a tacit assumption that Nrf2 plays an equally important 
role in man, although there have been very few investigations in this context, and it will be important to 
determine the importance of, and potential value of targeting, Nrf2 in human drug and chemical toxicities. 
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Target Organ Compound Phenotype of Nrf2-/- Mice Reference(s) 
Liver Acetaminophen Increased hepatocellular necrosis [5,6,9-12] 
2-Amino-3-methylimidazo[4,5-f]quinolone  Increased incidence and multiplicity of 
hepatocellular adenoma/carcinoma 
[13] 
1-Bromopropane Increased hepatocellular necrosis [14] 
Cadmium chloride Increased hepatic haemorrhage/necrosis [11,15] 
Carbon tetrachloride Delayed repair of hepatic necrosis [11,16] 
Diquat dibromide Increased hepatocellular necrosis [17] 
Ferric ammonium citrate Increased hepatic siderosis/necrosis [18] 
Furosemide Increased hepatocellular necrosis [11,19] 
Lapatinib Increased serum alanine/aspartate 
aminotransferase levels 
[20] 
Lithocholic acid Increased hepatocellular/ductal necrosis [11,21] 
Pentachlorophenol Increased hepatocellular adenoma and 
cholangio- fibrosis/carcinoma 
[22,23] 
Phalloidin Increased hepatic haemorrhage/necrosis [11,24] 
Piperonyl butoxide Increased hepatocellular adenoma  [22] 
Pyrazole Increased hepatocellular necrosis [25] 
Sodium arsenite Increased hepatic necrosis [26] 
2,3,7,8-Tetrachlorodibenzo-p-dioxin  Increased hepatic degeneration/ 
inflammation 
[27] 
Lung Bleomycin Increased pulmonary inflammation/ 
fibrosis  
[28,29] 
Butylated hydroxytoluene Increased pulmonary haemorrhage and 
alveolar destruction 
[4] 
Carrageenan Increased alveolar edema and neutrophil 
infiltration  
[30,31] 
Cigarette smoke Increased alveolar destruction [32-34] 
Diesel exhaust particulate Increased mucal cell hyperplasia [35,36] 
Diquat dibromide Increased alveolar edema/destruction  [17] 
Elastase Increased pulmonary haemorrhage and 
alveolar destruction 
[37] 
Lipopolysaccharide (LPS) Increased pulmonary edema and 
neutrophil infiltration  
[38,39] 
Multi-walled carbon nanotubes Increased pulmonary inflammation and 
neutrophil infiltration 
[40] 
Ovalbumin Increased pulmonary inflammatory cell 
infiltration 
[41] 
Titanium dioxide (TiO2) nanoparticles Increased pulmonary inflammatory cell 
infiltration 
[42] 
Brain 6-Hydroxydopamine Increased striatal lesion volume [43] 
Kainic acid Increased seizure intensity and 
hippocampal neuron damage 
[44] 
LPS Increased hippocampal inflammation and 
microglial activation 
[45] 
Malonic acid Increased striatal lesion volume [46] 
Methamphetamine Increased gliosis and loss of striatal 
neurons 
[47] 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine  Increased gliosis and loss of striatal 
neurons 
[48-51] 
3-Nitropropionic acid  Increase striatal lesion volume and 
decreased motor function 
[46,52] 
Kidney Cisplatin Increased proximal tubule degeneration/ 
necrosis 
[53,54] 
Ferric nitrilotriacetate  Increased proximal tubule degeneration/ 
necrosis 
[55,56] 
Pristine Increased renal vascular permeability and 
glomerular autoantibody deposition 
[57] 
Streptozotocin Increased hyperglycemia and 
glomerulosclerosis  
[58-60] 
Skin Cinnamaldehyde Increased dermal edema and 
inflammatory cell infiltration 
[61] 
7,12-Dimethylbenz(a)anthracene &  Increased incidence of skin tumours [62] 
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12-O-tetradecanoylphorbol-13-acetate  
2,4-Dinitrochlorobenzene  Increased dermal edema and 
inflammatory cell infiltration 
[61,63] 
Bladder N-nitrosobutyl(4-hydroxybutyl)amine  Increased incidence of invasive/non-
invasive bladder carcinoma 
[64,65] 
Sodium arsenite Increased interstitial edema/congestion [26] 
GI tract 2-Amino-3-methylimidazo[4,5-f]quinolone Increased incidence of forestomach 
squamous cell hyperplasia 
[13] 
Benzo[a]pyrene Increased incidence of forestomach 
neoplasia 
[66,67] 
Dextran sulfate sodium  Increased loss of colonic crypts [68,69] 
Heart Doxorubicin Increased cardiac necrosis and loss of 
cardiac function 
[70] 
 
Table 2 – Drug and chemical toxicities, affecting major organs, which are exacerbated in Nrf2-/- mice.  Due 
to space constraints, single studies showing that Nrf2 protects against drug and chemical toxicities affecting 
the breast, ear, eye, foetus and ovary have been excluded. Given the focus of this article, studies 
demonstrating that Nrf2 protects against the adverse effects of mechanical injury (e.g. tissue trauma, 
ischemia-reperfusion), environmental insult (e.g. ultraviolet light, hyperoxia), inflammatory proteins or 
altered composition of diet have not been considered.  
 
 
4. Nrf2 protects against drug and chemical toxicity – Negative aspects 
 
A increasing body of evidence indicates that Nrf2 pathway activity is elevated in a large proportion of cancers, 
due to somatic mutations in the Nrf2 or Keap1 genes that render the latter unable to efficiently repress 
Nrf2 [71]. By regulating the expression of genes that coordinate important metabolic processes, and enabling 
cells to survive in a highly oxidative environment via the upregulation of antioxidant genes, it appears that 
Nrf2 can promote cancer cell proliferation [71]. Another unwelcome consequence of the increase in Nrf2 
activity in some tumours is their heightened levels of protective genes that serve to detoxify cytotoxic 
chemotherapeutics and antagonise their deleterious effects. A number of groups have provided proof-of-
concept that inhibition of Nrf2 (most commonly via RNAi knockdown) can resensitize some cancer cells to a 
formerly efficacious anti-cancer agent [71]. These observations have generated interest in the potential for 
inhibiting Nrf2 as a means of overcoming drug resistance in cancer patients. Notwithstanding the fact that 
relatively few small molecule inhibitors of Nrf2 have been described, and that mechanisms of action are 
unclear in many cases [72], it is important to consider that many established chemotherapeutic drugs (e.g. 
cisplatin, bleomycin, doxorubicin; Table 2) are associated with off-target toxicities against which Nrf2 
protects. Therefore, it is possible that systemic coadjuvant inhibition of Nrf2 could enhance cancer cell killing 
but also exacerbate adverse effects in other organs. To address this paradox, it will be important to explore 
therapeutic strategies through which Nrf2 can be modulated, ideally in a manner that specifically targets 
cancer cells, to provide a more favourable balance between efficacy and off-target toxicity. The identification 
of such strategies is vital to make the translation of this approach to patients more feasible. 
 
5. Nrf2 directs an adaptive response to chemical and oxidative stress – Relevance to chemical risk 
assessment 
 
The activity of Nrf2 is primarily regulated by its interaction with its redox-sensitive cytosolic repressor 
Keap1 [73]. We and others have provided direct evidence for the chemical modification of specific cysteine 
residues in Keap1 by electrophilic compounds that stimulate Nrf2 signalling [73]. It is thought that this ability 
to ‘sense’ reactive chemical entities and oxidative species underpins the rapid accumulation of Nrf2 protein 
and consequent increased expression of its target genes that are typically observed in cells exposed to 
chemical stressors, although other mechanisms have been proposed [73]. In an effort to exploit the 
responsiveness of the Nrf2 pathway to oxidative stress in order to improve human hazard prediction, in 
recent years several reporter cell lines have been engineered to stably express luciferase under the 
transcriptional control of one or more AREs cloned from the promoter region of an Nrf2 target gene. One 
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such platform, the KeratinoSens assay, has recently been approved by the Organisation for Economic 
Cooperation and Development (OECD) for use in an integrated testing strategy for the in vitro detection of 
skin sensitizers [74], an area that has seen rapid progress following the recent European Union ban on the 
use of animals for testing of cosmetic products. A different reporter cell line, known as CellSensor ARE-
bla [75], is one of 30 being used in the Tox21 initiative to screen thousands of compounds in high-throughput 
with the aim of identifying structure-activity signatures that could be used to better predict toxicity in 
humans, and in turn reduce reliance on animal testing. By considering perturbation of the Nrf2 pathway 
alongside other important stress responses, and by multiplexing these assays with evaluation of cell viability 
to distinguish specific pathway activation from non-specific cytotoxic events, Tox21 promises to give a 
systems perspective to hazard identification that may shed light on important chemical and molecular 
distinctions between sets of compounds that commonly activate Nrf2 signalling yet are associated with 
beneficial (e.g. cytoprotective, chemopreventive) and deleterious (e.g. cytotoxic) effects in cells, animals 
and/or man. In many cases, these distinctions may be largely a function of concentration and time, but a 
deeper understanding will aid the identification of compounds with potential therapeutic applications and 
those that pose a risk of toxicity. 
 
5. Future directions 
 
The above represents a concise overview of our current understanding of the relationship between Nrf2 and 
chemical toxicity. Given the overwhelming evidence for a protective role of Nrf2 in mice, it will be necessary 
to establish whether a similar function is served in humans. In particular, it will be important to determine 
whether an individual's Nrf2 status predicts their susceptibility to a given drug or chemical toxicity. For 
example, single nucleotide polymorphisms in the human Nrf2 gene have been correlated with risk of various 
diseases [76]. It will be important to determine whether these or other polymorphisms render carriers more 
susceptible to the adverse effects of certain drugs. Based on the findings of these and other investigations, 
and dependent on the identification of more potent and specific Nrf2 modulators, it is possible that Nrf2 
activity could be manipulated to improve the therapeutic index of a drug, by bolstering the endogenous 
buffer against its adverse effects or, in some cases, by improving its therapeutic efficacy. In the coming years, 
the challenge for pharmacologists and toxicologists is to harness an ever-increasing knowledge of pathway 
biology and a burgeoning clinical experience of targeting Nrf2 to aid the development of safe and effective 
new drugs and identify strategies for improving the use of existing medicines in patients. 
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